Tarsus Pharmaceuticals, Inc. Operating Income Loss

• Tarsus Pharmaceuticals, Inc. showed an increase of +41.1% in Operating Income Loss from 2024 to 2025.
• This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Tarsus Pharmaceuticals, Inc.'s Operating Income Loss has declined by 1,551.2%.
• Historical annual values: Fiscal year 2025: -$70.97 million | Fiscal year 2024: -$120.57 million | Fiscal year 2023: -$143.16 million | Fiscal year 2022: -$62.71 million | Fiscal year 2021: -$12.16 million | Fiscal year 2020: -$27.00 million | Fiscal year 2019: -$4.30 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026